Literature DB >> 2252272

The ras oncogenes in human lung cancer.

S Rodenhuis1, R J Slebos.   

Abstract

The three well-characterized genes of the ras gene family H-ras, K-ras, and N-ras, code for closely related 21-kD proteins that have a role in the transduction of growth signals. The ras proteins acquire transforming potential when a point mutation in the gene leads to replacement of an amino acid in one of the critical positions 12, 13, or 61. Overexpression of the normal protein, usually associated with gene amplification, can have similar effects. The detection of mutationally activated ras genes has been facilitated by the development of oligonucleotide hybridization assays that allow the identification of each possible mutation at the critical sites. Employment of the polymerase chain reaction has greatly increased the sensitivity of these assays. Studies of human lung cancer have shown that adenocarcinoma is the only subtype associated with ras mutations. These occur in about 30% of primary tumors. In almost all cases, the mutation is present in codon 12 of the K-ras gene. No mutations have been observed to date in tumors of nonsmokers, suggesting that the mutation may result from exposure to carcinogenic ingredients of tobacco smoke. Amplifications of ras genes were shown to be very uncommon in clinically early stages of lung cancer. Analysis of the clinical data of patients who were operated on for adenocarcinoma of the lung shows that K-ras mutations are not associated with particular histologic characteristics of the tumors or with specific presenting features. Patients with K-ras mutations, however, had significantly worse survival than did those without an activation.

Entities:  

Mesh:

Year:  1990        PMID: 2252272     DOI: 10.1164/ajrccm/142.6_Pt_2.S27

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  30 in total

1.  Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.

Authors:  Hua Wang; Matthew B Schabath; Ying Liu; Olya Stringfield; Yoganand Balagurunathan; John J Heine; Steven A Eschrich; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2015-11-12       Impact factor: 4.785

2.  Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium.

Authors:  Eugenia C Pacheco-Pinedo; Amy C Durham; Kathleen M Stewart; Ashley M Goss; Min Min Lu; Francesco J Demayo; Edward E Morrisey
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

3.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

4.  Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells.

Authors:  Romel Somwar; David Shum; Hakim Djaballah; Harold Varmus
Journal:  J Biomol Screen       Date:  2009-12

5.  Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer.

Authors:  Mark Shapiro; Gal Akiri; Cynthia Chin; Juan P Wisnivesky; Mary B Beasley; Todd S Weiser; Scott J Swanson; Stuart A Aaronson
Journal:  Ann Surg       Date:  2013-03       Impact factor: 12.969

6.  Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma.

Authors:  Xia Xu; Jason R Rock; Yun Lu; Christopher Futtner; Brian Schwab; Justin Guinney; Brigid L M Hogan; Mark W Onaitis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

Review 7.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

8.  Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Authors:  R M Przygodzki; S D Finkelstein; J C Langer; P A Swalsky; N Fishback; A Bakker; D G Guinee; M Koss; W D Travis
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

9.  Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

Authors:  Karin E Finberg; Lecia V Sequist; Victoria A Joshi; Alona Muzikansky; Julie M Miller; Moonjoo Han; Javad Beheshti; Lucian R Chirieac; Eugene J Mark; A John Iafrate
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

10.  Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.

Authors:  Geoffrey D Girnun; Liang Chen; Jessica Silvaggi; Ronny Drapkin; Lucian R Chirieac; Robert F Padera; Rabi Upadhyay; Scott B Vafai; Ralph Weissleder; Umar Mahmood; Elnaz Naseri; Stephanie Buckley; Danan Li; Jeremy Force; Kate McNamara; George Demetri; Bruce M Spiegelman; Kwok-Kin Wong
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.